Evenity® (romosozumab-aqqg)
Effective 4/1/2020

Plan
☑ MassHealth
☑ Commercial/Exchange
☐ Pharmacy Benefit
☐ Medical Benefit (NLX)
Program Type
☐ Prior Authorization
☐ Quantity Limit
☐ Step Therapy

Specialty Limitations

Specialty Medications
All Plans | Phone: 866-814-5506 | Fax: 866-249-6155

Non-Specialty Medications
MassHealth | Phone: 877-433-7643 | Fax: 866-255-7569
Commercial | Phone: 800-294-5979 | Fax: 888-836-0730
Exchange | Phone: 855-582-2022 | Fax: 855-245-2134

Medical Specialty Medications (NLX)
All Plans | Phone: 844-345-2803 | Fax: 844-851-0882

Contact Information

Overview
Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Coverage Guidelines
Authorization may be granted for a total of 12 months for members who are currently receiving treatment with Evenity excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members with a diagnosis of postmenopausal osteoporosis when ANY the following criteria are met, and documentation is provided:

1. Member has a history of fragility fractures OR
2. Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix A) and meets ANY of the following criteria:
   a. Member has indicators of higher fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [less than or equal to -3.5], or increased fall risk)
   b. Member has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate (See Appendix B)

Limitations
Approvals are limited to a maximum of 12 months of therapy
Appendices

Appendix A: WHO Fracture Risk Assessment Tool

- High FRAX fracture probability: 10 year major osteoporotic fracture risk ≥ 20% or hip fracture risk ≥ 3%.
- 10-year probability; calculation tool available at: https://www.sheffield.ac.uk/FRAX/
- The estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture if glucocorticoid treatment is greater than 7.5 mg per day.

Appendix B: Clinical reasons to avoid oral bisphosphonate therapy

- Esophageal abnormality that delays emptying such as stricture of achalasia
- Active upper gastrointestinal problem (e.g., dysphagia, gastritis, duodenitis, erosive esophagitis, ulcers)
- Inability to stand or sit upright for at least 30 to 60 minutes
- Inability to take at least 30 to 60 minutes before first food, drink, or medication of the day
- Renal insufficiency (creatinine clearance <35 mL/min)
- History of intolerance to an oral bisphosphonate

References


Review History

11/20/2019 – Reviewed P&T
11/25/2019 – Reviewed and approved DCC
01/22/2020 – Approved P&T Mtg
Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.